Vilazodone (Viibryd)

What it treats

Vilazodone is approved by the U.S. Food and Drug Administration to treat major depressive disorder in adults.

Off-label uses are limited. Some prescribers use it in generalized anxiety, though the evidence base is thinner than for SSRIs. Off-label means a purpose the label doesn't formally list even though evidence and practice support it.

How it works

Vilazodone acts on serotonin, a chemical messenger the brain's nerve cells use to pass messages. It does two things at once. It slows the reuptake of serotonin, so more of it stays available between cells, and it also partially turns on the 5-HT1A receptor, a docking site on cells that helps regulate serotonin signaling.

Combining reuptake inhibition with 5-HT1A partial agonism is thought to smooth out some of the early side effects that SSRIs can cause and, importantly, tends to spare sexual function more than a plain SSRI does.

Receptor mechanism (detail)

Vilazodone is a SPARI (serotonin partial agonist and reuptake inhibitor). It inhibits the serotonin transporter (SERT) and acts as a 5-HT1A partial agonist. The 5-HT1A partial agonism resembles the mechanism of buspirone and is thought to explain the lower rates of sexual dysfunction and the modest anxiolytic effect. Vilazodone requires food for absorption (approximately doubles bioavailability compared with the fasted state); without food, blood levels drop enough that treatment can fail.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Titration: 10 mg once daily with food for 7 days, then 20 mg once daily with food for 7 days, then 40 mg once daily with food. The target is 40 mg per day for most people. Doses below 40 mg are considered sub-therapeutic for the antidepressant effect.

Safety monitoring

• Take with food. Bioavailability drops by roughly 50% without food, which can look like non-response.
• Suicidality in the first 4 weeks, especially under age 25 (FDA boxed warning).
• Serotonin syndrome, avoid MAOIs; caution with other serotonergic drugs.
• Bleeding risk with NSAIDs or anticoagulants (as with SSRIs).
• Hyponatremia in older adults.
• GI side effects (diarrhea, nausea) are common early and dose-related.
• Reassess at 2, 4, and 6 to 8 weeks, then every 3 months.

What to expect

Common side effects

Common side effects include:

• Diarrhea.
• Nausea.
• Headache.
• Insomnia or vivid dreams.
• Dry mouth.

If a side effect is severe, or it isn't improving after a few weeks, that's a conversation to have with the prescriber rather than a reason to stop on your own.

Serious side effects and warnings

Serious problems are uncommon, but a few are worth knowing.

Boxed warning. Like all antidepressants, vilazodone carries an FDA boxed warning that it can increase suicidal thoughts and behaviors in children, teenagers, and young adults under 25, especially in the first weeks of treatment or after a dose change. This doesn't mean the medication harms most people. It means the early period deserves close attention.

• Serotonin syndrome. A rare reaction from too much serotonin activity, most likely with MAOIs, tramadol, triptans, or St. John's wort. Agitation, fast heartbeat, high fever, muscle rigidity, and confusion. Medical emergency.
• Bleeding risk. Vilazodone can make bleeding and bruising more likely, especially with NSAIDs, aspirin, or anticoagulants.
• Low sodium. More common in older adults; watch for headache, confusion, weakness.
• Mood switch in bipolar disorder. An antidepressant can occasionally trigger a manic state, which is one reason accurate diagnosis matters.

Sexual side effects

Vilazodone has lower rates of sexual side effects than most SSRIs and SNRIs. That's one of its main appeals. Reduced desire, delayed orgasm, or arousal difficulty can still occur but tend to be milder or less frequent than with a standard SSRI.

Weight, appetite, and sleep

Vilazodone is broadly weight-neutral. Sleep effects are variable; some report insomnia early on, which often eases.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Vilazodone comes as tablets, taken once daily with food. The titration (10 to 20 to 40 mg over two weeks) helps reduce early GI side effects. If a person is stuck at 20 mg because of side effects, some prescribers slow the titration further. Below 40 mg, the drug is generally considered sub-therapeutic.

Missed doses and interactions

If you miss a dose, take it with food when you remember, unless it's almost time for the next dose. Skip the missed dose and carry on. Don't take two doses to make up for one.

Several interactions matter. Vilazodone must not be combined with MAOIs, and a gap is needed when switching. Other strongly serotonergic drugs (tramadol, triptans, dextromethorphan, St. John's wort, meperidine, linezolid, methylene blue) raise serotonin syndrome risk. NSAIDs and blood thinners raise bleeding risk. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) raise vilazodone levels; strong CYP3A4 inducers (rifampin, carbamazepine) lower them. Alcohol adds to CNS effects. Give every prescriber and pharmacist a full list of your medications and supplements, including over-the-counter ones.

Stopping and tapering

Vilazodone isn't a controlled substance and isn't habit-forming in the usual sense.

The body does adjust to it, and stopping abruptly can cause discontinuation symptoms: dizziness, flu-like feelings, irritability, and sleep disturbance. A gradual taper planned with a prescriber avoids most of this.

Pregnancy and breastfeeding

This is an area where individual circumstances matter and the decision belongs with a clinician. Untreated depression carries its own risks during pregnancy, and vilazodone passes into breast milk. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so the specific risks and benefits can be weighed for their situation.

Cost and generic availability

Vilazodone is available as a generic, which has brought cost down. The brand name Viibryd contains the same active medication as generic vilazodone and works the same way. Coverage varies between insurance plans.

Common questions

Why does vilazodone have to be taken with food? Without food, the body absorbs about half as much of the drug. That's enough to change a therapeutic dose into a sub-therapeutic one and make the medication look ineffective. A real meal, not just a snack, is the standard advice.

Is it better for sexual side effects than an SSRI? On average, yes. Rates are lower than with sertraline, escitalopram, or paroxetine. Not zero, though.

How is it different from vortioxetine? Both act on serotonin in more than one way. Vortioxetine is described as multimodal (SERT plus several receptor actions); vilazodone is a SPARI (SERT plus 5-HT1A partial agonism). Clinically both tend to be gentler on sexual function than plain SSRIs.

Why is diarrhea so common? The 5-HT1A activity and the reuptake inhibition together seem to push GI motility more than a standard SSRI does. Taking with food and titrating slowly usually get past this.

How long until vilazodone works? Some early effects can show within the first weeks. The fuller mood effect usually takes four to six weeks at 40 mg.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• What counts as "with food," and what if I can't take it that way?
• Which side effects should I expect early, and which should I call about?
• How long should I plan to take it?
• If we decide to stop it later, how would we do that safely?

Sources

This guide draws on current prescribing information and public health references and current as of June 8, 2026. It is reviewed for clinical accuracy and updated as guidance changes.

• U.S. Food and Drug Administration. Vilazodone hydrochloride (Viibryd) prescribing information.
• MedlinePlus, U.S. National Library of Medicine. Vilazodone.
• National Institute of Mental Health. Mental health medications.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder.
• National Institute for Health and Care Excellence (NICE). NG222, Depression in adults.